Edition:
United Kingdom

CTI Biopharma Corp (CTIC.OQ)

CTIC.OQ on NASDAQ Stock Exchange Capital Market

3.73USD
16 Feb 2018
Change (% chg)

$0.03 (+0.81%)
Prev Close
$3.70
Open
$3.70
Day's High
$3.79
Day's Low
$3.70
Volume
84,782
Avg. Vol
62,367
52-wk High
$4.78
52-wk Low
$2.46

Select another date:

Fri, Feb 9 2018

BRIEF-CTI BioPharma Prices Underwritten Public Offering Of $60 Million Of Common Stock

* CTI BIOPHARMA PRICES UNDERWRITTEN PUBLIC OFFERING OF $60 MILLION OF COMMON STOCK

BRIEF-CTI Biopharma Announces Launch Of Follow-On Offering

* CTI BIOPHARMA CORP - INTENDS TO USE NET PROCEEDS OF OFFERING TO COMPLETE PAC203 CLINICAL TRIAL, COMPLETE REVIEW OF PACRITINIB MAA BY EMA, AMONG OTHERS Source text for Eikon:

BRIEF-CTI Biopharma Provides Corporate And European Regulatory Update

* CTI BIOPHARMA PROVIDES CORPORATE AND EUROPEAN REGULATORY UPDATE

BRIEF-CTI BioPharma to receive $10 mln milestone payment for Trisenox

* CTI BIOPHARMA TO RECEIVE $10 MILLION MILESTONE PAYMENT FOR TRISENOX®

BRIEF-Spotlight Therapeutics Inc Says It Has Raised $7.3 Million In Equity Financing

* SPOTLIGHT THERAPEUTICS INC FILES TO SAY IT HAS RAISED $7.3 MILLION IN EQUITY FINANCING - SEC FILING​

BRIEF-CTI Biopharma Corp Says Co Entered Into A Loan And Security Agreement​

* CTI BIOPHARMA CORP - ‍ON NOVEMBER 28, 2017, CTI BIOPHARMA CORP ENTERED INTO A LOAN AND SECURITY AGREEMENT​

BRIEF-CTI BIOPHARMA FILES FOR MIXED SHELF OF UP TO $200 MLN‍​

* CTI BIOPHARMA CORP FILES FOR MIXED SHELF OF UP TO $200 MILLION – SEC FILING‍​ Source text: (http://bit.ly/2zo6CPZ) Further company coverage:

BRIEF-CTI Biopharma reports third quarter 2017 financial results

* CTI Biopharma Corp - ‍total revenues for q3 were $1.7 million compared to $4.4 million Source text for Eikon: Further company coverage:

BrainStorm enrolls first patients in advanced ALS stem cell trial

TEL AVIV BrainStorm Cell Therapeutics said the first patients have been enrolled in a late-stage trial of its treatment for amyotrophic lateral sclerosis (ALS) at Massachusetts General Hospital and UC Irvine Medical Center in California.

BrainStorm enrolls first patients in advanced ALS stem cell trial

TEL AVIV, Oct 16 BrainStorm Cell Therapeutics said the first patients have been enrolled in a late-stage trial of its treatment for amyotrophic lateral sclerosis (ALS) at Massachusetts General Hospital and UC Irvine Medical Center in California.

Select another date: